| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6070441 | Journal of the American Academy of Dermatology | 2016 | 11 Pages |
Abstract
Etanercept in pediatric patients was generally well tolerated and efficacy was maintained in those who remained in the study for up to 264Â weeks.
Keywords
sPGAOLEPASI 90HRQOLJIAFDASAEOpen-label extensionCDCPASI 75Juvenile idiopathic arthritisetanerceptstatic Physician Global AssessmentPediatric populationLong-term safetyPASIFood and Drug Administrationadverse eventSerious adverse eventOpen-labelCenters for Disease Control and Preventionpsoriasis area and severity indexplaque psoriasisHealth-related quality of life
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Amy S. MD, Elaine C. MD, David M. MD, Kara Creamer MS, Mona MD, Jan MD, David H. MD, Greg MD, Richard G. MD,